title: Recent diabetes issues affecting the primary care clinician.
abstract: Diabetes accounts for millions of office visits each year to primary care offices in the United States. Successful care of the patient with type 2 diabetes requires not only focus on glucose management but also on comorbidities such as hypertension, dyslipidemia and obesity which are closely linked to microvascular and macrovascular complications. Primary care clinicians must stay abreast of frequently published diabetes literature and new treatments to care for these increasingly complex patients. Metformin and its effect on B12 absorption continues to be an issue encountered by clinicians in daily clinical practice. There has also been recent discussion regarding the increased risk of diabetes with statins; data to date on this issue have been conflicting. Rosiglitazone continues to face public scrutiny and there are now Food and Drug Administration regulations regarding its increased risk of cardiovascular disease. Liraglutide and saxagliptin represent new treatment options for type 2 diabetes, increasing the available options for treating this complex disease. A review of the primary literature involving these topics is provided.
authors: University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville 32610, USA. ksando@cop.ufl.edu
authors: Karen R
authors: KR
authors: Sando
authors: Jose
authors: J
authors: Barboza
authors: Crystal
authors: C
authors: Willis
authors: James
authors: J
authors: Taylor
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use; D000069450:Liraglutide; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D011320:Primary Health Care; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use; D014806:Vitamin B 12 Deficiency / Q000139:chemically induced
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D008687:Metformin; C502994:saxagliptin; D000218:Adamantane